Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial

Study answer

What this study found

This packet does not report numerical outcome results, p-values, or a completed efficacy conclusion for xanthohumol. The trial was designed to evaluate safety, tolerability, inflammation-related biomarkers, gut permeability, bile acid metabolism, xanthohumol metabolism, gut microbiota, and health-related quality of life over 8 weeks, with laboratory safety tests repeated every 2 weeks and adverse events monitored throughout. Baseline values and effect estimates for the key outcomes are not provided here, so no interpretable efficacy signal can be extracted from the source packet.

Study & population

Phase I, randomized, triple-masked, placebo-controlled clinical trial in healthy adults without chronic disease.

Intervention

Xanthohumol was given orally as a 99+% pure 24 mg/day dose in an orange capsule for 8 weeks.

Key limitation

Phase I study in a small sample of healthy adults, limiting power and generalizability.

View full study detailsView sourceOpen PDF

Original abstract